EGFR tyrosine kinase domain mutations in human gliomas

被引：60

作者：

Marie, Y

Carpentier, AF

Omuro, AMP

Sanson, M

Thillet, J

Hoang-Xuan, K

Delattre, JY

机构：

[1] Hop La Pitie Salpetriere, Serv Neurol Mazarin, Paris, France

[2] Hop La Pitie Salpetriere, INSERM, UMR 495, Paris, France

[3] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA

来源：

NEUROLOGY | 2005年 / 64卷 / 08期

关键词：

D O I：

10.1212/01.WNL.0000158654.07080.B0

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Gefitinib is an epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitor effective in patients with lung cancer with mutations in exons 19 and 21 of the EGFR tyrosine kinase domain. In this study, the authors tested the presence of such mutations in 95 gliomas including glioblastomas, anaplastic oligodendrogliomas, and low-grade gliomas. No mutation was found, which suggests that the biology of EGFR in gliomas is different from lung cancer and that this may be a factor in the resistance of glioblastomas to gefitinib.

引用

页码：1444 / 1445

页数：2

共 10 条

[1] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[2] Targeting targeted therapy [J].

Green, MR .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2191-2193

[3]

Li B, 2003, CANCER RES, V63, P7443

[4] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[5] Epidermal growth factor receptor antagonists: Novel therapy for the treatment of high-grade gliomas [J].

Nathoo, N ;

Vogelbaum, MA .

NEUROSURGERY, 2004, 54 (06) :1480-1488

[6] EGFR and cancer prognosis [J].

Nicholson, RI ;

Gee, JMW ;

Harper, ME .

EUROPEAN JOURNAL OF CANCER, 2001, 37 :S9-S15

[7] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[8] EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [J].

Pao, W ;

Miller, V ;

Zakowski, M ;

Doherty, J ;

Politi, K ;

Sarkaria, I ;

Singh, B ;

Heelan, R ;

Rusch, V ;

Fulton, L ;

Mardis, E ;

Kupfer, D ;

Wilson, R ;

Kris, M ;

Varmus, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13306-13311

[9]

Rich JN, 2004, NEW ENGL J MED, V351, P1260

[10] Phase II trial of gefitinib in recurrent glioblastoma [J].

Rich, JN ;

Reardon, DA ;

Peery, T ;

Dowell, JM ;

Quinn, JA ;

Penne, KL ;

Wikstrand, CJ ;

Van Duyn, LB ;

Dancey, JE ;

McLendon, RE ;

Kao, JC ;

Stenzel, TT ;

Rasheed, BKA ;

Tourt-Uhlig, SE ;

Herndon, JE ;

Vredenburgh, JJ ;

Sampson, JH ;

Friedman, AH ;

Bigner, DD ;

Friedman, HS .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :133-142

← 1 →